Pertuzumab Intravenous and Robidone

• Generic Name: pertuzumab
• Dosage Forms: n.a.
• Other Brand Names: Perjeta

Pertuzumab injection is used to treat breast cancer that has spread to other parts of the body. It is used together with other cancer medicines (eg, docetaxel, trastuzumab) to treat patients with HER2-positive breast cancer. The HER2 protein is produced by some breast tumors. Pertuzumab is a monoclonal antibody that interferes with the growth of this protein, which is eventually destroyed by the body.

Pertuzumab is also used as part of a complete treatment regimen for early breast cancer before surgery and as an additional treatment for breast cancer that is at high risk for occurring again.

Pertuzumab is to be given only by or under the immediate supervision of your doctor.

• Generic Name: hydrocodone
• Dosage Forms: n.a.
• Other Brand Names: Hysingla ER, Zohydro ER, Vantrela ER

Hydrocodone is used to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and when other pain medicines did not work well enough or cannot be tolerated. It should not be used to treat pain that you only have once in a while or "as needed". Hydrocodone belongs to the group of medicines called narcotic analgesics (pain medicines) that act on the central nervous system (CNS) to relieve pain.

When hydrocodone is used for a long time, it may become habit-forming, causing mental or physical dependence. However, people who have continuing pain should not let the fear of dependence keep them from using narcotics to relieve their pain. Mental dependence (addiction) is not likely to occur when narcotics are used for this purpose. Physical dependence may lead to withdrawal side effects if treatment is stopped suddenly. However, severe withdrawal side effects can usually be prevented by gradually reducing the dose over a period of time before treatment is stopped completely.

This medicine is available only with your doctor's prescription. Hysingla™ is available only under a restricted distribution program called the Opioid Analgesic REMS (Risk Evaluation and Mitigation Strategy) program.